Immune ecotypes may offer more refined patient stratification for ccRCC than current biomarkers
Immune Ecotypes May Guide Kidney Cancer Treatment
This mini review explores the use of immune ecotypes to identify treatment-responsive profiles in patients with advanced clear cell renal ce…
New review proposes four immune subtypes in kidney cancer that could explain why some patients respond to immunotherapy and others don't.
Spontaneous regression observed in a patient with cystic renal cell carcinoma
Kidney tumor shows spontaneous regression before surgery for diagnosis
A case report describes a patient with a cystic mass in the left kidney that exhibited spontaneous regression following an initial period of…
A rare case of kidney cancer showed unexpected shrinking before surgery, highlighting why early intervention is vital for diagnosing complex…
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
Genetic markers linked to blood pressure drugs raise kidney cancer risk
This meta-analysis of Mendelian randomization and colocalization analyses found that genetic perturbations equivalent to antihypertensive dr…
Genetic data suggests certain blood pressure targets may increase clear cell renal cell carcinoma risk, a finding that warrants attention fo…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
New Test Finds Hidden TB in Kidney Tissue
A retrospective cohort study of 86 patients with surgically resected renal tissue found CFP10 immunohistochemical staining had 91.8% sensiti…
A new kidney test spots hidden tuberculosis by finding a specific protein that standard methods often miss, helping doctors catch the infect…
Research across Urologic Neoplasms
Related studies from across the Urologic Neoplasms family.
Belzutifan and Lenvatinib Combination Improves Progression Free Survival in Advanced Renal Cell Carcinoma
Trial shows new drug combo slows advanced kidney cancer growth
A Phase 3 trial demonstrates that the belzutifan-lenvatinib combination significantly extends progression-free survival in patients with adv…
A new drug combination helped slow the growth of advanced kidney cancer in patients who did not respond to earlier treatments.
First-line immune checkpoint inhibitors plus anti-angiogenic therapy improve progression-free survival and response rates in advanced RCC
Combination Therapy Shows Better Outcomes for Advanced Renal Cell Carcinoma
This meta-analysis of 4,977 patients found that first-line immune checkpoint inhibitors combined with anti-angiogenic therapy significantly …
A new combination of immune checkpoint inhibitors and anti-angiogenic therapy shows better survival rates than standard treatment for advanc…
cGAS-STING pathway activation drives inflammation, fibrosis, and podocyte injury in various kidney diseases
New research identifies a key pathway in kidney disease progression
This systematic review synthesizes preclinical data on the cGAS-STING signaling pathway's role in acute kidney injury, chronic kidney diseas…
A specific signaling pathway called cGAS-STING acts as a central hub, linking inflammation and metabolism to several types of serious kidney…
Comparative Efficacy of Robot Assisted Radical Nephrectomy and Open Surgery for IVC Thrombus
Robot assisted surgery shows fewer complications for certain kidney cancers
Meta-analysis indicates robot-assisted radical nephrectomy reduces blood loss, transfusion needs, and major complications in patients with r…
Robotic surgery may reduce blood loss and hospital stays for patients with specific types of kidney cancer involving the inferior vena cava.
FH-deficient renal cell carcinoma case shows rapid bone metastasis despite adjuvant therapy
Rare Kidney Cancer Case Shows Aggressive Spread Despite Treatment
This case report and literature review describes a 42-year-old woman with FH-deficient renal cell carcinoma and uterine leiomyomas, treated …
A rare kidney cancer in a 42-year-old woman spread quickly despite surgery and therapy, highlighting the need for early genetic testing.
Repeat ablation provides favorable outcomes for local recurrence after primary ablation in renal cell carcinoma
Local treatments show mixed results for recurring kidney cancer
This meta-analysis of 45 studies evaluates the efficacy of various local salvage therapies for patients with local recurrence of renal cell …
New data shows that while some local treatments work well for recurring kidney cancer, others face challenges with distant spread.
Disease-free survival shows strong correlation with overall survival in localized renal cell carcinoma
Disease free survival predicts long term outcomes for kidney cancer
This systematic review and trial-level meta-analysis of 9594 patients with localized renal cell carcinoma found a strong correlation between…
A large analysis shows that tracking how long patients stay cancer-free can help doctors predict overall survival in kidney cancer cases.
Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
Retroperitoneal approach in single-port robot-assisted partial nephrectomy may reduce blood loss and hospital stay
Retroperitoneal approach may offer benefits for kidney cancer surgery
This meta-analysis of 384 patients compares transperitoneal and retroperitoneal approaches for single-port robot-assisted partial nephrectom…
A new look at surgical methods suggests the retroperitoneal approach may reduce blood loss and hospital stays for patients with renal cancer…
High PTTG1 expression correlates with poorer survival and advanced disease in various solid tumors
High levels of PTTG1 protein linked to worse cancer outcomes
This meta-analysis of 22 studies from 21 articles analyzed the prognostic value of PTTG1 expression across multiple solid tumors. High PTTG1…
A review of 22 studies shows that high levels of the PTTG1 protein are linked to shorter survival times in several types of solid tumors.
Percutaneous thermal ablation shows higher local recurrence than robot-assisted partial nephrectomy for localized renal cell carcinoma
Meta-analysis shows higher local recurrence risk with thermal ablation for kidney cancer
This systematic review and meta-analysis of 2,516 patients with localized renal cell carcinoma compared percutaneous thermal ablation to rob…
A large analysis of kidney cancer treatments found thermal ablation had higher local recurrence rates than partial nephrectomy, though overa…
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Questions about Renal Clear Cell Carcinoma
Can a cystic mass in Renal Clear Cell Carcinoma shrink on its own?
Yes, a cystic mass in renal clear cell carcinoma can shrink on its own, but this is extremely rare and does not replace the need for surgical treatment.
Full answer →